IS2634B - Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi - Google Patents

Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Info

Publication number
IS2634B
IS2634B IS8567A IS8567A IS2634B IS 2634 B IS2634 B IS 2634B IS 8567 A IS8567 A IS 8567A IS 8567 A IS8567 A IS 8567A IS 2634 B IS2634 B IS 2634B
Authority
IS
Iceland
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
IS8567A
Other languages
English (en)
Other versions
IS8567A (is
Inventor
Andrew V Schally
Nagy Attila
Zhi Cai Ren
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2634(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of IS8567A publication Critical patent/IS8567A/is
Publication of IS2634B publication Critical patent/IS2634B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8567A 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi IS2634B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (2)

Publication Number Publication Date
IS8567A IS8567A (is) 2006-11-09
IS2634B true IS2634B (is) 2010-06-15

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4734A IS2178B (is) 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður
IS8567A IS2634B (is) 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4734A IS2178B (is) 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður

Country Status (27)

Country Link
US (2) US5843903A (is)
EP (2) EP0863917B1 (is)
JP (2) JP3987575B2 (is)
KR (2) KR100467899B1 (is)
CN (2) CN1166597C (is)
AT (2) ATE401305T1 (is)
AU (1) AU709539B2 (is)
BR (1) BR9611647B1 (is)
CA (2) CA2238574C (is)
CZ (1) CZ297297B6 (is)
DE (2) DE69637604D1 (is)
DK (2) DK0863917T3 (is)
EA (1) EA001372B1 (is)
ES (2) ES2205067T3 (is)
HK (1) HK1052920B (is)
HU (1) HU229870B1 (is)
IL (3) IL134685A (is)
IS (2) IS2178B (is)
MX (1) MX9804119A (is)
NO (2) NO324035B1 (is)
NZ (1) NZ322054A (is)
PL (3) PL191781B1 (is)
PT (2) PT863917E (is)
SK (2) SK284392B6 (is)
UA (1) UA67722C2 (is)
WO (1) WO1997019954A1 (is)
ZA (1) ZA969709B (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350919A1 (en) 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
EP1235598A2 (en) * 1999-11-12 2002-09-04 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
DK1242438T3 (da) 1999-12-29 2007-02-12 Immunogen Inc Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
WO2001081426A2 (en) * 2000-04-26 2001-11-01 Biosynthema Inc. Rgd (arg-gly-asp) coupled to (neuro)peptides
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
PL369336A1 (en) 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US20050171014A1 (en) * 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
AU2003220011B2 (en) 2002-03-01 2008-05-29 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
KR20050012224A (ko) * 2002-05-21 2005-01-31 다이이찌 산토리 파마 가부시키가이샤 그렐린 함유 의약 조성물
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
MXPA04011651A (es) 2002-05-24 2005-03-07 Angiotech Pharm Inc Composiciones y metodo para recubrir implantes medicos.
DE60325240D1 (de) 2002-09-26 2009-01-22 Angiotech Int Ag Perivaskuläre hüllen
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
US20080132458A1 (en) * 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
HRP20160631T1 (hr) * 2006-09-06 2016-07-15 Æterna Zentaris Gmbh Konjugati disorazola i njihovi derivati sa staničnovezajućim molekulama, novi derivati disorazola, postupci njihove pripreme i njihove uporabe
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
AU2009235897B2 (en) * 2008-04-11 2012-04-12 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
BRPI1008039A2 (pt) * 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
WO2012073217A1 (en) 2010-12-02 2012-06-07 Nerviano Medical Sciences S.R.L. Process for the preparation of morpholinyl anthracycline derivatives
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
JP6602834B2 (ja) * 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
CA3118743A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
ES2094136T3 (es) * 1989-12-19 1997-01-16 Pharmacia Spa Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
EP0450461B1 (en) * 1990-04-06 1995-09-06 The Administrators of The Tulane Educational Fund LHRH Analogs
DE69110519T2 (de) * 1990-04-06 1995-11-30 Univ Tulane Somatostatinanaloge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
AU709539B2 (en) 1999-09-02
IS4734A (is) 1998-05-05
CN1137136C (zh) 2004-02-04
HK1052920B (zh) 2005-03-04
ATE251179T1 (de) 2003-10-15
ATE401305T1 (de) 2008-08-15
PT1384710E (pt) 2008-10-08
CN1405127A (zh) 2003-03-26
JP2000502055A (ja) 2000-02-22
NO982252L (no) 1998-05-15
HK1017363A1 (en) 1999-11-19
IL119691A0 (en) 1997-02-18
NO982252D0 (no) 1998-05-15
IS8567A (is) 2006-11-09
ZA969709B (en) 1997-08-25
CA2471775C (en) 2008-01-29
DK1384710T3 (da) 2008-11-17
JP2007045845A (ja) 2007-02-22
HUP9903771A3 (en) 2000-07-28
DE69637604D1 (de) 2008-08-28
EA199800492A1 (ru) 1998-12-24
EP1384710B1 (en) 2008-07-16
EA001372B1 (ru) 2001-02-26
KR100445754B1 (ko) 2004-12-08
PL191781B1 (pl) 2006-07-31
PL326865A1 (en) 1998-10-26
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
KR19990071672A (ko) 1999-09-27
SK284392B6 (sk) 2005-03-04
CN1166597C (zh) 2004-09-15
CA2238574A1 (en) 1997-06-05
HUP9903771A2 (hu) 2000-02-28
JP3987575B2 (ja) 2007-10-10
MX9804119A (es) 1998-09-30
PL188786B1 (pl) 2005-04-29
PL187230B1 (pl) 2004-06-30
ES2310222T3 (es) 2009-01-01
PT863917E (pt) 2004-02-27
SK284672B6 (sk) 2005-08-04
BR9611647B1 (pt) 2010-03-09
CZ135798A3 (cs) 1998-10-14
IL134685A0 (en) 2001-04-30
CN1202903A (zh) 1998-12-23
CA2471775A1 (en) 1997-06-05
EP0863917A1 (en) 1998-09-16
JP4778405B2 (ja) 2011-09-21
CA2238574C (en) 2004-10-19
EP0863917B1 (en) 2003-10-01
EP1384710A1 (en) 2004-01-28
CZ297297B6 (cs) 2006-11-15
NO324035B1 (no) 2007-07-30
BR9611647A (pt) 1999-02-23
DE69630233D1 (de) 2003-11-06
KR20040037176A (ko) 2004-05-04
DE69630233T2 (de) 2004-08-05
WO1997019954A1 (en) 1997-06-05
HU229870B1 (en) 2014-10-28
US6184374B1 (en) 2001-02-06
AU7572296A (en) 1997-06-19
US5843903A (en) 1998-12-01
NO20051111L (no) 2005-03-01
HK1052920A1 (en) 2003-10-03
IL134685A (en) 2002-12-01
SK62898A3 (en) 1999-06-11
UA67722C2 (en) 2004-07-15
IS2178B (is) 2006-12-15
KR100467899B1 (ko) 2005-01-24
DK0863917T3 (da) 2004-01-19
NZ322054A (en) 1999-04-29

Similar Documents

Publication Publication Date Title
IS2634B (is) Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi
DE3566251D1 (en) Novel intermediate and method for its preparation
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
ES8603408A1 (es) Un procedimiento para la preparacion de un compuesto de 2-oxindol-1-carboxamida
ATE384063T1 (de) Sammlungen von verbindungen
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
NZ510489A (en) Pyrrolo-benzodiazine derivatives optionally linked to a solid support useful for treating gene based diseases or bacterial, parasitic and viral infections
IT1283782B1 (it) Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MY108849A (en) Novel compound
DE69737376D1 (de) Verfahren zur Synthese einer Oxonolverbindung
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
AR248396A1 (es) Procedimiento para la obtencion de 1, 5-diaril pirazoles utiles como antiinflamatorios y compuestos intermediarios para su uso exclusivo en el procedimiento.
MX9205408A (es) Metodo para tratar hipertension.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
RU95105338A (ru) Трициклические цефемсульфоны, способ их получения, композиция
AR015458A1 (es) Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
ES8301230A1 (es) Un procedimiento para la preparacion de 1-fenil-5-amidotetrazoles.
TH19545A (th) อนุพันธ์เพปไทด์
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii
ECSP993154A (es) PROCEDIMIENTO PARA LA PREPARACION DE PIRAZOLO (4,3,d) -PIRIMIDIN -7-ONAS Y SUS INTERMEDIOS
HUP9802890A2 (hu) Hidroxil-amin származékok és alkalmazásuk, valamint eljárás és készítmény kultúrnövények időjárási szélsőségekkel szembeni ellenállásának növelésére